Which has stronger earnings and valuation, AMGN or AZN?

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.93 $7.71B $16.09 25.05 Astrazeneca $58.74B 4.14 $10.23B $6.69 23.45

Is AMGN or AZN more profitable?

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% Astrazeneca 17.02% 31.45% 13.20%

Does the media prefer AMGN or AZN?

In the previous week, Astrazeneca had 20 more articles in the media than Amgen. MarketBeat recorded 30 mentions for Astrazeneca and 10 mentions for Amgen. Amgen's average media sentiment score of 0.51 beat Astrazeneca's score of 0.34 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 9 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has better earnings & valuation, AZN or BIIB?

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.14 $10.23B $6.69 23.45 Biogen $9.89B 3.28 $1.29B $5.65 38.92

Is AZN or BIIB more profitable?

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Biogen 8.32% 11.18% 6.88%

Does the media prefer AZN or BIIB?

In the previous week, Astrazeneca had 18 more articles in the media than Biogen. MarketBeat recorded 30 mentions for Astrazeneca and 12 mentions for Biogen. Biogen's average media sentiment score of 0.94 beat Astrazeneca's score of 0.34 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 9 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Biogen 5 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MRNA or AZN?

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 39.02 -$2.82B -$7.99 N/A Astrazeneca $58.74B 4.14 $10.23B $6.69 23.45

Is MRNA or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to MRNA or AZN?

In the previous week, Moderna had 11 more articles in the media than Astrazeneca. MarketBeat recorded 41 mentions for Moderna and 30 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.34 beat Moderna's score of 0.19 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 7 Very Positive mention(s) 14 Positive mention(s) 10 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral Astrazeneca 9 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NVAX or AZN?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.54 $440.30M -$1.52 N/A Astrazeneca $58.74B 4.14 $10.23B $6.69 23.45

Is NVAX or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to NVAX or AZN?

In the previous week, Astrazeneca had 25 more articles in the media than Novavax. MarketBeat recorded 30 mentions for Astrazeneca and 5 mentions for Novavax. Novavax's average media sentiment score of 0.61 beat Astrazeneca's score of 0.34 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 9 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, AZN or ABBV?

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.14 $10.23B $6.69 23.45 AbbVie $61.16B 7.61 $4.23B $3.54 74.37

Is AZN or ABBV more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% AbbVie 9.80% -422.07% 14.34%

Does the media favor AZN or ABBV?

In the previous week, AbbVie had 29 more articles in the media than Astrazeneca. MarketBeat recorded 59 mentions for AbbVie and 30 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.74 beat Astrazeneca's score of 0.34 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 9 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral AbbVie 24 Very Positive mention(s) 12 Positive mention(s) 18 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Astrazeneca (AZN) Competitors

$156.91 -0.79 (-0.50%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$157.15 +0.24 (+0.15%)

As of 10/2/2026 08:00 PM Eastern

Compare

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy Astrazeneca stock or one of its competitors? Astrazeneca's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Astrazeneca compare to Amgen?

Amgen (NASDAQ:AMGN) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.5%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Amgen pays out 62.6% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years.

Amgen has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.93	$7.71B	$16.09	25.05
Astrazeneca	$58.74B	4.14	$10.23B	$6.69	23.45

Amgen currently has a consensus price target of $385.25, indicating a potential downside of 4.41%. Astrazeneca has a consensus price target of $206.67, indicating a potential upside of 31.71%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72

In the previous week, Astrazeneca had 20 more articles in the media than Amgen. MarketBeat recorded 30 mentions for Astrazeneca and 10 mentions for Amgen. Amgen's average media sentiment score of 0.51 beat Astrazeneca's score of 0.34 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	9 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Astrazeneca	17.02%	31.45%	13.20%

76.5% of Amgen shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Amgen beats Astrazeneca on 12 of the 20 factors compared between the two stocks.

How does Astrazeneca compare to Biogen?

Astrazeneca (NYSE:AZN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Astrazeneca has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Biogen. Astrazeneca is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.14	$10.23B	$6.69	23.45
Biogen	$9.89B	3.28	$1.29B	$5.65	38.92

Astrazeneca currently has a consensus target price of $206.67, suggesting a potential upside of 31.71%. Biogen has a consensus target price of $230.14, suggesting a potential upside of 4.67%. Given Astrazeneca's stronger consensus rating and higher possible upside, research analysts plainly believe Astrazeneca is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Astrazeneca had 18 more articles in the media than Biogen. MarketBeat recorded 30 mentions for Astrazeneca and 12 mentions for Biogen. Biogen's average media sentiment score of 0.94 beat Astrazeneca's score of 0.34 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	9 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Biogen	5 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca has a net margin of 17.02% compared to Biogen's net margin of 8.32%. Astrazeneca's return on equity of 31.45% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Biogen	8.32%	11.18%	6.88%

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Astrazeneca beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to Moderna?

Moderna (NASDAQ:MRNA) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	39.02	-$2.82B	-$7.99	N/A
Astrazeneca	$58.74B	4.14	$10.23B	$6.69	23.45

In the previous week, Moderna had 11 more articles in the media than Astrazeneca. MarketBeat recorded 41 mentions for Moderna and 30 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.34 beat Moderna's score of 0.19 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	7 Very Positive mention(s)	14 Positive mention(s)	10 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral
Astrazeneca	9 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

75.3% of Moderna shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Astrazeneca has a net margin of 17.02% compared to Moderna's net margin of -141.43%. Astrazeneca's return on equity of 31.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Astrazeneca	17.02%	31.45%	13.20%

Moderna presently has a consensus target price of $77.83, suggesting a potential downside of 59.04%. Astrazeneca has a consensus target price of $206.67, suggesting a potential upside of 31.71%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72

Moderna has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Astrazeneca beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to Novavax?

Novavax (NASDAQ:NVAX) and Astrazeneca (NYSE:AZN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

53.0% of Novavax shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novavax has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

In the previous week, Astrazeneca had 25 more articles in the media than Novavax. MarketBeat recorded 30 mentions for Astrazeneca and 5 mentions for Novavax. Novavax's average media sentiment score of 0.61 beat Astrazeneca's score of 0.34 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	9 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

Novavax presently has a consensus price target of $14.00, indicating a potential upside of 33.84%. Astrazeneca has a consensus price target of $206.67, indicating a potential upside of 31.71%. Given Novavax's higher probable upside, research analysts clearly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.54	$440.30M	-$1.52	N/A
Astrazeneca	$58.74B	4.14	$10.23B	$6.69	23.45

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Astrazeneca	17.02%	31.45%	13.20%

Summary

Astrazeneca beats Novavax on 11 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to AbbVie?

Astrazeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years. Astrazeneca is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, AbbVie had 29 more articles in the media than Astrazeneca. MarketBeat recorded 59 mentions for AbbVie and 30 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.74 beat Astrazeneca's score of 0.34 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	9 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
AbbVie	24 Very Positive mention(s)	12 Positive mention(s)	18 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.14	$10.23B	$6.69	23.45
AbbVie	$61.16B	7.61	$4.23B	$3.54	74.37

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
AbbVie	9.80%	-422.07%	14.34%

Astrazeneca has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 31.71%. AbbVie has a consensus price target of $272.39, suggesting a potential upside of 3.47%. Given Astrazeneca's higher possible upside, equities analysts clearly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

AbbVie beats Astrazeneca on 12 of the 20 factors compared between the two stocks.

Get Astrazeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	Astrazeneca	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$243.34B	$12.27B	$7.15B	$22.78B
Dividend Yield	2.77%	2.65%	2.54%	3.73%
P/E Ratio	23.45	802.26	275.67	27.75
Price / Sales	4.14	940.01	656.66	21.39
Price / Cash	12.14	86.66	78.87	38.23
Price / Book	5.00	10.52	10.93	4.64
Net Income	$10.23B	$2.86B	$3.51B	$1.08B
7 Day Performance	-5.87%	-1.58%	-2.00%	-1.06%
1 Month Performance	-3.51%	-5.55%	-6.19%	-5.60%
1 Year Performance	N/A	-2.19%	8.03%	5.09%

Astrazeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN Astrazeneca	4.9143 of 5 stars	$156.91 -0.5%	$206.67 +31.7%	-8.0%	$243.34B	$58.74B	23.45	96,100	Analyst Upgrade
AMGN Amgen	3.2523 of 5 stars	$414.61 +2.1%	$383.46 -7.5%	+35.3%	$224.15B	$38.10B	25.77	31,500
BIIB Biogen	3.5815 of 5 stars	$227.60 +0.5%	$230.14 +1.1%	+37.5%	$33.63B	$10.03B	40.28	7,500	Trending News
MRNA Moderna	1.9409 of 5 stars	$198.88 +2.1%	$76.72 -61.4%	+566.9%	$79.40B	$1.94B	N/A	4,700	Trending News Analyst Downgrade
NVAX Novavax	2.1311 of 5 stars	$10.63 +0.3%	$14.00 +31.7%	+10.6%	$1.75B	$1.12B	N/A	749

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AZN) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrazeneca (AZN) Competitors